Insider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Acquires $15,642.00 in Stock

Key Points

• Director James Topper of NewAmsterdam Pharma purchased 660 shares at an average cost of $23.70, increasing his total ownership to approximately 3.03 million shares.
• The company's stock price recently hit $24.49, with a market cap of $2.76 billion, and it has reported a negative net margin of 259.07%.
• Analysts have given NewAmsterdam Pharma a consensus rating of "Moderate Buy" with a target price of $41.55, indicating optimism about its future performance.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James N. Topper bought 660 shares of the business's stock in a transaction dated Monday, September 15th. The shares were bought at an average cost of $23.70 per share, for a total transaction of $15,642.00. Following the purchase, the director directly owned 3,028,524 shares in the company, valued at approximately $71,776,018.80. This represents a 0.02% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

NewAmsterdam Pharma Trading Down 0.1%

NewAmsterdam Pharma stock traded down $0.04 during trading hours on Friday, hitting $26.69. 1,314,247 shares of the stock traded hands, compared to its average volume of 999,900. The company has a market cap of $3.01 billion, a PE ratio of -16.48 and a beta of -0.01. The firm's 50-day moving average price is $24.10 and its two-hundred day moving average price is $20.94. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $27.35.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.37. The company had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. On average, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. increased its holdings in NewAmsterdam Pharma by 23.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock worth $409,052,000 after acquiring an additional 3,061,224 shares in the last quarter. Wellington Management Group LLP increased its stake in NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after buying an additional 2,222,900 shares in the last quarter. RA Capital Management L.P. raised its holdings in NewAmsterdam Pharma by 14.6% during the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company's stock valued at $207,544,000 after acquiring an additional 1,293,938 shares during the period. Woodline Partners LP lifted its position in shares of NewAmsterdam Pharma by 108.7% in the fourth quarter. Woodline Partners LP now owns 2,430,782 shares of the company's stock valued at $62,471,000 after acquiring an additional 1,266,105 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock worth $54,566,000 after acquiring an additional 1,062,359 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on NAMS shares. Cantor Fitzgerald assumed coverage on NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price objective for the company. Wells Fargo & Company started coverage on shares of NewAmsterdam Pharma in a report on Monday, August 25th. They set an "overweight" rating and a $45.00 price objective for the company. Citigroup assumed coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price on the stock. Stifel Nicolaus assumed coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $41.55.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.